Derek Luney, MD
Cardiovascular Disease · Conover, NCNPI 1679535363
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 132 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 21.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,358 and has fallen 78.7% since, to $289 in 2022. That places this record below the midpoint for cardiovascular disease clinicians in NC, where the typical reported total is $1,959.
Across 132 payments — averaging $15.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$432
- Amgen$410
- Novartis$167
- AstraZeneca$126
- Medtronic$104
- Pfizer$77
- plus $720 from 17 others
What the payments were for
- Food & beverage$2,037100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 29 | $432 |
| Amgen | 28 | $410 |
| Novartis | 12 | $167 |
| AstraZeneca | 9 | $126 |
| Medtronic(2 entities) | 6 | $104 |
| Pfizer | 5 | $77 |
| Sanofi-aventis U.S. LLC | 6 | $76 |
| Chiesi USA, Inc. | 4 | $76 |
| Abbott | 4 | $71 |
| Boehringer Ingelheim | 4 | $67 |
| Amarin Pharma, Inc. | 3 | $57 |
| Impulse Dynamics (USA) Inc. | 1 | $51 |
| Portola Pharmaceuticals, LLC | 3 | $47 |
| E.r. Squibb & Sons, L.L.C. | 3 | $36 |
| Arbor Pharmaceuticals, Inc. | 2 | $36 |
| Astellas Pharma US Inc | 2 | $33 |
| Otsuka America Pharmaceutical, Inc. | 2 | $32 |
| Irhythm Technologies, Inc. | 2 | $31 |
| Bardy Diagnostics, Inc. | 1 | $26 |
| Regeneron Healthcare Solutions, Inc. | 2 | $26 |
| Edwards Lifesciences | 2 | $23 |
| Nuwellis, Inc. | 1 | $18 |
| Novo Nordisk | 1 | $15 |
How this compares
$2,037 in reported general payments places this provider in the 50th percentile of 727 cardiovascular disease providers in North Carolina.
See all cardiovascular disease providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other cardiovascular disease in Conover
- R WilliamsDurham$2.1M
- Marat FudimDurham$902K
- Jonathan PicciniDurham$767K
- Michael RinaldiCharlotte$722K
- Markus SchererCharlotte$526K
- Robert MentzDurham$489K
- Sean PokorneyMorganton$477K
- Adrian HernandezDurham$409K
- Sanjeev GulatiCharlotte$406K
- Richard BrowneCharlotte$379K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.